Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

314 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ongoing genome doubling promotes evolvability and immune dysregulation in ovarian cancer.
McPherson A, Vázquez-García I, Myers MA, Zatzman M, Al-Rawi D, Weiner A, Freeman S, Mohibullah N, Satas G, Williams MJ, Ceglia N, Zhang AW, Li J, Lim JLP, Wu M, Choi S, Havasov E, Grewal D, Shi H, Kim M, Schwarz R, Kaufmann T, Dinh KN, Uhlitz F, Tran J, Wu Y, Patel R, Ramakrishnan S, Kim D, Clarke J, Green H, Ali E, DiBona M, Varice N, Kundra R, Broach V, Gardner GJ, Roche KL, Sonoda Y, Zivanovic O, Kim SH, Grisham RN, Liu YL, Viale A, Rusk N, Lakhman Y, Ellenson LH, Tavaré S, Aparicio S, Chi DS, Aghajanian C, Abu-Rustum NR, Friedman CF, Zamarin D, Weigelt B, Bakhoum SF, Shah SP. McPherson A, et al. Among authors: aghajanian c. bioRxiv [Preprint]. 2024 Jul 15:2024.07.11.602772. doi: 10.1101/2024.07.11.602772. bioRxiv. 2024. PMID: 39071261 Free PMC article. Preprint.
Tracking clonal evolution of drug resistance in ovarian cancer patients by exploiting structural variants in cfDNA.
Williams MJ, Vázquez-García I, Tam G, Wu M, Varice N, Havasov E, Shi H, Satas G, Lees HJ, Lee JJ, Myers MA, Zatzman M, Rusk N, Ali E, Shah RH, Berger MF, Mohibullah N, Lakhman Y, Chi DS, Abu-Rustum NR, Aghajanian C, McPherson A, Zamarin D, Loomis B, Weigelt B, Friedman CF, Shah SP. Williams MJ, et al. Among authors: aghajanian c. bioRxiv [Preprint]. 2024 Aug 23:2024.08.21.609031. doi: 10.1101/2024.08.21.609031. bioRxiv. 2024. PMID: 39229105 Free PMC article. Preprint.
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.
Green AK, Zhou Q, Iasonos A, Zammarrelli WA, Weigelt B, Ellenson LH, Chhetri-Long R, Shah P, Loh J, Hom V, Selenica P, Erinjeri J, Petkovska I, Chandarlapaty S, Cohen S, Grisham R, Konner J, Rubinstein MM, Tew W, Troso-Sandoval T, Aghajanian C, Makker V. Green AK, et al. Among authors: aghajanian c. Clin Cancer Res. 2024 Nov 19. doi: 10.1158/1078-0432.CCR-24-1999. Online ahead of print. Clin Cancer Res. 2024. PMID: 39561275
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer.
Grisham R, Monk BJ, Van Nieuwenhuysen E, Moore KN, Fabbro M, O'Malley DM, Oaknin A, Thaker P, Oza AM, Colombo N, Gershenson D, Aghajanian CA, Choi CH, Lee YC, Mirza MR, Coleman RL, Cobb L, Harter P, Lustgarten S, Youssoufian H, Banerjee S. Grisham R, et al. Among authors: aghajanian ca. Int J Gynecol Cancer. 2024 Oct 7:ijgc-2024-005919. doi: 10.1136/ijgc-2024-005919. Online ahead of print. Int J Gynecol Cancer. 2024. PMID: 39375168
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
Brown J, Miller A, Holman LL, Backes F, Nagel C, Bender D, Miller DS, Powell MA, Westin SN, Bonebrake A, Muller CY, Secord AA, Crane E, Schorge J, Tew WP, Sood AK, Bookman MA, Aghajanian C, Gershenson DM. Brown J, et al. Among authors: aghajanian c. Gynecol Oncol. 2024 Nov;190:283-290. doi: 10.1016/j.ygyno.2024.09.002. Epub 2024 Sep 12. Gynecol Oncol. 2024. PMID: 39265466 Clinical Trial.
ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability-high (MSI-H) molecular subtype.
Brodeur MN, Selenica P, Ma W, Moufarrij S, Dagher C, Basili T, Abu-Rustum NR, Aghajanian C, Zhou Q, Iasonos A, Ellenson LH, Weigelt B, Chui MH. Brodeur MN, et al. Among authors: aghajanian c. Mol Oncol. 2024 Oct;18(10):2356-2368. doi: 10.1002/1878-0261.13698. Epub 2024 Jul 19. Mol Oncol. 2024. PMID: 39031567 Free PMC article.
Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer.
Andres S, Finch L, Iasonos A, Zhou Q, Girshman J, Chhetri-Long R, Green H, Jang D, O'Cearbhaill R, Kyi C, Cohen S, Friedman C, Makker V, Chi DS, Sonoda Y, Chiang S, Aghajanian C, Weigelt B, Grisham RN. Andres S, et al. Among authors: aghajanian c. Gynecol Oncol. 2024 Oct;189:30-36. doi: 10.1016/j.ygyno.2024.06.026. Epub 2024 Jul 10. Gynecol Oncol. 2024. PMID: 38991472 Clinical Trial.
Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
Manning-Geist BL, Sullivan MW, Zhou Q, Iasonos A, Selenica P, Stallworth C, Liu YL, Long Roche K, Gordhandas S, Aghajanian C, Chi D, O'Cearbhaill R, Grisham RN, Chui MH. Manning-Geist BL, et al. Among authors: aghajanian c. Gynecol Oncol. 2024 Sep;188:52-57. doi: 10.1016/j.ygyno.2024.06.008. Epub 2024 Jun 27. Gynecol Oncol. 2024. PMID: 38941962
314 results